Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Pairing HCV testing and treatment eliminates the need to navigate the medical system.
Sofosbuvir-based regimens were well tolerated and cure rates were high in this population.
The number of people treated for hepatitis C hit a low point during the COVID-19 pandemic.
People who received a shortened course of antiviral therapy were less likely to be cured.
Timely testing and treatment could improve outcomes for young people who inject drugs.
Louisiana saw a bump-up in HCV prescriptions after the alternate model was introduced.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
With many hepatitis C treatments on the market today, patients may ask which hepatitis C treatment is right for me? What’s the difference?
After inmates filed a class action lawsuit, Nevada agreed to treat all prisoners living with hepatitis C.
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
These recommendations are based on the World Health Organization’s guidelines.
Homeless people, incarcerated individuals and people with mental health conditions achieved a high cure rate.
The assurance arrives as the pharma giant cuts off most emergency access to remdesivir, a potential COVID-19 treatment.
Gilead Sciences’ direct-acting antiviral regimen was previously approved for adults.
Six weeks, compared with the standard 12 weeks, was associated with an unacceptably high rate of viral relapse.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.